SLC25A22 and malignant colon neoplasm: In KRAS-mutated colon cancer cells, SLC25A22-mediated Gln breakdown reduces H3K4me3 methylation, stimulates the activation of the Wnt/beta-catenin signaling pathway, and diminishes the sensitivity of colon cancer cells to chemotherapeutic agents (35).